Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus TRIMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus TRIMOX.
AMPICILLIN AND SULBACTAM vs TRIMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity. Sulbactam is a β-lactamase inhibitor that irreversibly inhibits a broad range of β-lactamases, preventing degradation of ampicillin.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
1.5-3 g (ampicillin 1-2 g + sulbactam 0.5-1 g) IV/IM every 6 hours. Maximum daily dose of sulbactam is 4 g.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours depending on infection severity.
None Documented
None Documented
Ampicillin: 1-1.8 hours; sulbactam: 1-1.5 hours. Prolonged in renal impairment (e.g., creatinine clearance <30 mL/min: up to 8-12 hours).
Terminal elimination half-life: 1-1.5 hours (normal renal function); in renal impairment (CrCl <10 mL/min), extends to 6-20 hours, requiring dose adjustment.
Primarily renal (70-75% unchanged ampicillin, 75-80% unchanged sulbactam). Biliary excretion accounts for ~25% of ampicillin and ~20% of sulbactam. Fecal elimination is minor (<5%).
Renal: 50-85% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minimal, <5%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic